GENELUX Corp
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 3 insiders sold shares within a monthSince Nov 3, 2026+9.7
Trials
- GNLXGenelux Corporation10Calm
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Signing up patientsPhase 3186 patientsMain results: Dec 2026 - GNLXGenelux Corporation10Calm
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Signing up patientsPhase 2142 patientsMain results: Feb 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
16 sales (15 not pre-planned) · 0 purchases
- Cappello JosephChief Technical Officer · Nov 3, 2026Sold 668 sharesabout $1 thousand · not pre-planned
- Zindrick ThomasPresident and CEO · Nov 3, 2026Sold 3,089 sharesabout $6 thousand · not pre-planned
- Yu YongChief Scientific Officer · Nov 3, 2026Sold 668 sharesabout $1 thousand · not pre-planned
- Cappello JosephChief Technical Officer · Aug 31, 2026Sold 10,257 sharesabout $28 thousand · not pre-planned
- Zindrick ThomasPresident and CEO · Aug 31, 2026Sold 34,463 sharesabout $92 thousand · not pre-planned
- Yu YongChief Scientific Officer · Aug 31, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.